COVID-19 treatments - 
Information for medical providers

Updated 3/23/2022

Getting vaccinated is the best way for your patients to prevent COVID-19. Encourage your patients to get vaccinated as soon as possible and to get a booster dose if they are eligible for one. The Utah Department of Health has patient education materials, videos, graphics, and other materials to help you talk to your patients about the risks and benefits of COVID-19 vaccination. Learn more about COVID-19 vaccination.  

There are several treatments that can help prevent severe illness or hospitalization from COVID-19, including monoclonal antibody therapy and antiviral medications. These treatments are most effective when given early and the sooner it is given the better.

Letter to medical providers from Dr. Michelle Hofmann, deputy director at the Utah Department of Health, about the availability of COVID-19 therapeutics in Utah.

  • Previous letters from Dr. Michelle Hofmann regarding availability of COVID-19 novel therapeutics in Utah
    (12/29/20211/28/2022  / 2/10/2022).


COVID-19 therapeutics locator

This interactive map is maintained by the U.S. Department of Health and Human Services. Providers are able to search for therapeutics by therapy and zip code. This tool is for providers only, as these medications require a prescription by a licensed and authorized provider. Patients should not contact locations listed on the locator.

Therapeutics locator

Utah Crisis Standards of Care Scarce COVID Therapeutics Guidelines

These guidelines were developed by the Scarce Medications Allocation Subcommittee of the Utah Crisis Standards of Care Workgroup to ensure that scarce COVID-19 treatments are prescribed fairly and to patients who are most likely to benefit from them. This subcommittee consists of physicians trained in critical care, infectious disease, pediatrics, and internal medicine; hospital pharmacists, and experts in allocation frameworks and ethics.

Download PDF

Our self-assessment tool can help your patients know if they likely meet the current Emergency Use Authorization for Bebtelovimab. This tool is not intended to replace advice or medical assessments for COVID-19 treatment from a medical provider. You or your patients may also call the COVID-19 Hotline at 1-800-456-7707 for help finding infusion sites. Hotline operators are available from Monday - Friday, 7am-7pm, Saturday, 8am-4pm, Closed Sunday.

Self-assessment tool for Bebtelovimab

Monoclonal antibody therapy (Bebtelovimab)

Monoclonal antibody treatments are effective at keeping people out of the hospital, but don’t help people as much once they are sick enough with COVID-19 to be admitted into the hospital.

Monoclonal antibody treatment should NOT be used to prevent COVID-19. It is not a therapy to help people just “feel better” but is intended to prevent severe outcomes among people who are most likely to be hospitalized or die from COVID-19. People who benefit the most from this treatment are typically older or have complex underlying medical conditions.

Early data shows only one monoclonal antibody therapy medication (Bebtelovimab) effectively works against the Omicron BA.2 variant. It is unlikely that the other monoclonal antibody therapies will be effective treatments against Omicron BA.2 and help prevent hospitalizations.

Which patients are eligible to receive monoclonal antibody therapy? 

The FDA Bebtelovimab Emergency Use Authorization outlines which patients may be recommended for treatment with Bebtelovimab. Patients who qualify for mAb must:

  • Test positive for SARS-CoV-2.
  • Currently have symptoms of COVID-19.
  • Be within the first 7 days of symptom onset.
  • Be at high risk for severe illness from COVID-19 due to things like age and underlying medical conditions. 

Bebtelovimab is not authorized for use in patients who:

  • Are hospitalized due to COVID-19, or
  • Require oxygen therapy due to COVID-19, or
  • Require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity).

Where can my patients get monoclonal antibody therapy?

Patients can receive treatment at hospitals and outpatient clinics throughout the state.

Patients should NOT show up to a treatment location without an appointment. Patients will be turned away if they don’t have an appointment.  

Current mAb treatment locations in Utah 

How much will this treatment cost my patients?

Medicare and Medicaid both cover the cost for infusion administration. Patients who are commercially insured may face potentially high deductibles or copays depending on their insurance plan. The insurance and health coverage landscape is complex. Commercial insurance covers about 22% of Utahns, other health coverage is provided through government plans, such as Medicare and Medicaid, and self-funded employer plans that are regulated at the federal level. 

Learn more about potential costs and coverage for mAb treatment.

Encourage your patients to ask the treatment provider if there are any costs with getting the treatment before they schedule their appointment so they know what to expect.



Who is eligible to receive a pre-exposure prophylaxis (PrEP) monoclonal antibody treatment (Evusheld)?

On Feb. 24, 2022, the FDA revised the emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab) to change the initial dose for the authorized use as pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric patients. Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorized in the U.S. for COVID-19 pre-exposure prophylaxis and the only COVID-19 antibody delivered as an intramuscular dose (300mg tixagevimab and 300mg cilgavimab).

Individuals who received only the initial dose of 300mg (150 mg of tixagevimab and 150 mg of cilgavimab) should receive an additional Evusheld dose as soon as possible. If a patient received their initial dose:

  • less than 3 months ago, that patient should receive a dose of 300mg (150 mg of tixagevimab and 150 mg of cilgavimab)
  • more than 3 months ago, that patient should receive a dose of 600mg (300 mg of tixagevimab and 300 mg of cilgavimab)
Any subsequent repeat dosing will be timed from the date of this additional Evusheld dose. 

Patients who have not received any doses of Evusheld should talk to their healthcare provider to determine whether, based on their individual circumstances, they are eligible to receive it. If they are eligible, they should receive the 600mg  (300 mg of tixagevimab and 300 mg of cilgavimab) dose.

People whose immune systems are so substantially weakened that they do not develop immunity from the vaccines or those who can’t be vaccinated because of severe allergic reactions are at increased risk for COVID-19. For those individuals, healthcare providers may recommend Evusheld as a way to offer protection in case those individuals become exposed to the COVID-19 virus.

Individuals receiving Evusheld must meet the following criteria:

  • Be at least 12 years old or older, and 
  • Weigh at least 88 pounds, and
  • Not currently infected with COVID-19, and
  • Have not had a known recent exposure to an individual infected with COVID-19.

Patients must also meet one of the two criteria below: 

  • Be severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, or   
  • Not recommended to receive COVID-19 vaccinations according to the approved or authorized dosage schedule due to a history of severe adverse reaction (severe allergic reaction) to a COVID-19 vaccine(s) or COVID-19 vaccine component(s).

Where can my patients get Evusheld?

The Utah Department of Health has allocated all available Evusheld treatments to select providers who are the most likely to care for patients who meet the criteria of being severely immunocompromised. It’s expected that these providers will provide Evusheld to both their own patients and facilitate referrals from unaffiliated providers with eligible patients in the order they are received.

Patients with questions about eligibility should first contact their existing specialty care provider for the qualifying immunocompromised condition to arrange a referral process. If a patient does not currently have a specialty care provider, they should start with their primary care provider.

Patients must qualify and have a doctor’s referral to get Evusheld treatment. Patients should NOT show up to a treatment location without an appointment. Patients will be turned away if they don’t have an appointment.


Pfizer’s antiviral medication, PAXLOVID, is authorized for use in people ages 12 and older who have tested positive for COVID-19 and are at high risk of severe illness from COVID-19, including hospitalization or death. Patients must begin taking PAXLOVID within 5 days of symptom onset. PAXLOVID isn’t recommended for patients with severe liver or kidney disease, it also may interact with other prescriptions a patient might be taking. It is not authorized for people who are hospitalized with COVID-19.

PAXLOVID is taken as a course of 30 pills, 3 pills are taken two times a day for 5 days.

The FDA Emergency Use Authorization provides the inclusion criteria for which patients qualify to receive PAXLOVID at this time. 


Merck’s antiviral medication, molnupiravir, is authorized for use in people ages 18 and older who have tested positive for COVID-19, are at high risk of severe illness, and when there are no other COVID-19 treatment options. It is not authorized for use in children. Molnupiravir is also not recommended for use by pregnant women. Molnupiravir can be especially useful for residents of long-term care and skilled nursing facilities who need to avoid stopping or altering their current treatments.   

Molnupiravir is taken as a course of 40 pills, 4 pills are taken two times a day for 5 days.

Remdesivir (Veklury)®

Remdesivir is an antiviral medicine that can help treat COVID-19 in patients needing hospitalization.